| Literature DB >> 32362599 |
Se Young Choi1, Byung Hoon Chi1, Tae-Hyoung Kim1, Bumjin Lim2, Wonchul Lee2, Dalsan You2, Choung-Soo Kim2.
Abstract
We investigated the relationship between positive surgical margin (PSM)-related factors and biochemical recurrence (BCR) and the ability of intraoperative frozen sections to predict significant PSM in patients with prostate cancer. The study included 271 patients who underwent robot-assisted laparoscopic prostatectomy with bilateral nerve sparing and maximal urethral preservation. Intraoperative frozen sections of the periurethra, dorsal vein, and bladder neck were analyzed. The ability of PSM-related factors to predict BCR and significant PSM was assessed by logistic regression. Of 271 patients, 108 (39.9%) had PSM and 163 (60.1%) had negative margins. Pathologic Gleason score ≥8 (18.9% vs 7.5%, P = 0.015) and T stage ≥T3a (51.9%vs 24.6%, P < 0.001) were significantly more frequent in the PSM group. Multivariate analysis showed that Gleason pattern ≥4 (vs <4; hazard ratio: 4.386; P = 0.0004) was the only significant predictor of BCR in the PSM cohort. Periurethral frozen sections had a sensitivity of 83.3% and a specificity of 84.2% in detecting PSM with Gleason pattern ≥4. Multivariate analysis showed that membranous urethra length (odds ratio [OR]: 0.79, P = 0.0376) and extracapsular extension of the apex (OR: 4.58, P = 0.0226) on magnetic resonance imaging (MRI) and positive periurethral tissue (OR: 17.85, P < 0.0001) were associated with PSM of the apex. PSM with Gleason pattern ≥4 is significantly predictive of BCR. Intraoperative frozen sections of periurethral tissue can independently predict PSM, whereas sections of the bladder neck and dorsal vein could not. Pathologic examination of these samples may help predict significant PSM in patients undergoing robot-assisted laparoscopic prostatectomy with preservation of functional outcomes.Entities:
Keywords: biochemical recurrence; frozen section; positive surgical margin; robotic-assisted prostatectomy
Year: 2021 PMID: 32362599 PMCID: PMC7831825 DOI: 10.4103/aja.aja_16_20
Source DB: PubMed Journal: Asian J Androl ISSN: 1008-682X Impact factor: 3.285
Basic characteristics of patients and tumors
| Age (year), mean±s.d. | 63.8±7.3 | 65.6±6.7 | 64.9±7.0 | 0.039 |
| Initial PSA (ng ml−1), mean±s.d. | 9.2±7.5 | 7.1±4.8 | 7.9±6.0 | 0.013 |
| Body mass index (kg m−2), mean±s.d. | 24.3±3.3 | 24.7±2.6 | 24.5±2.9 | 0.315 |
| Hypertension, | 70 (64.8) | 89 (54.6) | 112 (41.3) | 0.122 |
| Diabetes mellitus, | 23 (21.3) | 29 (17.8) | 52 (19.2) | 0.576 |
| Charlson comorbidity index, | ||||
| 0 | 9 (8.3) | 18 (11.0) | 27 (10.0) | 0.720 |
| 1 | 62 (57.4) | 94 (57.7) | 156 (57.6) | |
| ≥2 | 37 (34.3) | 51 (31.3) | 88 (32.5) | |
| D’Amico risk, | ||||
| Low | 2 (1.9) | 15 (9.2) | 17 (6.3) | 0.032 |
| Intermediate | 14 (13.0) | 14 (8.6) | 28 (10.3) | |
| High | 92 (85.2) | 134 (82.2) | 226 (83.4) | |
| Clinical T2 stage, | 78 (72.2) | 133 (81.6) | 211 (77.9) | 0.095 |
| Extracapsular invasion on MRI, | 30 (27.8) | 24 (14.7) | 54 (19.9) | 0.144 |
| Seminal vesicle invasion on MRI, | 7 (6.5) | 12 (7.4) | 19 (7.0) | 0.454 |
| Clinical Gleason score, | ||||
| 6 | 30 (27.8) | 52 (31.9) | 82 (30.3) | 0.014 |
| 7 | 48 (44.4) | 81 (49.7) | 129 (47.6) | |
| 8 | 14 (13.0) | 25 (15.3) | 39 (14.4) | |
| ≥9 | 16 (14.8) | 5 (3.1) | 21 (7.7) | |
| Prostate volume on TRUS (ml), mean±s.d. | 34.1±10.1 | 34.9±14.5 | 34.6±12.9 | 0.675 |
| Membranous urethra length on MRI (mm), mean±s.d. | 12.0±4.0 | 12.1±2.8 | 12.1±3.4 | 0.919 |
| Percent of positive core (%), mean±s.d. | 57.8±33.5 | 51.4±37.0 | 53.9±35.7 | 0.155 |
| Maximal tumor percent of positive core (%), mean±s.d. | 51.3±31.0 | 39.1±25.3 | 44.0±28.3 | 0.001 |
| Prostate volume (ml), mean±s.d. | 29.4±9.7 | 31.0±13.1 | 30.4±11.8 | 0.264 |
| Tumor volume (ml), mean±s.d. | 6.6±7.7 | 2.6±2.6 | 4.2±5.6 | <0.001 |
| Pathologic Gleason score, | ||||
| 6 | 12 (11.9) | 36 (22.5) | 48 (18.4) | 0.015 |
| 7 | 70 (69.3) | 112 (70.0) | 182 (69.7) | |
| 8 | 4 (4.0) | 3 (1.9) | 7 (2.7) | |
| ≥9 | 15 (14.9) | 9 (5.6) | 24 (9.2) | |
| Pathologic T stage, | ||||
| T2 | 52 (48.1) | 123 (75.5) | 175 (64.6) | <0.001 |
| T3a | 41 (38.0) | 28 (17.2) | 69 (25.5) | |
| T3b | 15 (13.9) | 12 (7.4) | 27 (10.0) | |
| Length of PSM (mm), mean±s.d. | 11.1±15.0 | 11.1±15.0 | ||
| Number of PSMs, | ||||
| 1 | 63 (58.3) | 63 (23.2) | ||
| ≥2 | 45 (41.7) | 45 (16.6) | ||
| Gleason pattern of PSM, | ||||
| <4 | 48 (44.4) | 48 (17.7) | ||
| ≥4 | 60 (55.6) | 60 (22.1) | ||
| Location of PSM, | ||||
| Apex | 62 (57.4) | 0 (0) | 62 (22.9) | |
| Base | 21 (19.4) | 0 (0) | 21 (7.7) | |
| Anterior | 37 (34.3) | 0 (0) | 37 (13.7) | |
| Posterolateral | 41 (38.0) | 0 (0) | 41 (15.1) | |
| Positive frozen section, | ||||
| Periurethra tissue | 44 (40.7) | 19 (11.7) | 63 (23.2) | <0.001 |
| Bladder neck | 6 (5.6) | 2 (1.2) | 8 (3.0) | 0.090 |
| Dorsal vein site | 15 (13.9) | 2 (1.2) | 17 (6.3) | <0.001 |
PSMs: positive surgical margins; NSM: negative surgical margin; s.d.: standard deviation; PSA: prostate-specific antigen; MRI: magnetic resonance imaging; TRUS: transrectal ultrasonography
Cox hazard analysis of factors associated with biochemical recurrence-free survival
| PSM versus NSM | 3.310 | 1.900–5.740 | <0.0001 | 2.681 | 1.474–4.878 | 0.0012 | |||
| Gleason pattern of PSM ( | |||||||||
| Gleason pattern <4 | 1.440 | 0.660–3.140 | 0.3640 | 1.212 | 0.522–2.813 | 0.6551 | 1.000 | Reference | |
| Gleason pattern ≥4 | 6.670 | 3.670–12.100 | <0.0001 | 4.434 | 2.347–8.380 | <0.0001 | 4.386 | 1.938–9.928 | 0.0004 |
| Length of PSM ( | |||||||||
| <8 mm | 2.310 | 1.110–4.840 | 0.0260 | 2.497 | 1.156–5.394 | 0.0198 | 1.000 | Reference | |
| ≥8 mm | 4.160 | 2.230–8.090 | <0.0001 | 2.804 | 1.441–5.456 | 0.0024 | 1.236 | 0.536–2.854 | 0.6191 |
| Number of PSMs ( | |||||||||
| 1 | 2.670 | 1.390–5.140 | 0.0030 | 2.448 | 1.240–4.828 | 0.0098 | 1.000 | Reference | |
| ≥2 | 4.250 | 2.230–8.090 | <0.0001 | 3.056 | 1.471–6.347 | 0.0027 | 1.147 | 0.445–2.955 | 0.7767 |
| Location of PSM ( | |||||||||
| Apex | 3.660 | 1.990–6.730 | <0.0001 | 3.861 | 1.919–7.768 | 0.0002 | 1.000 | Reference | |
| Base | 5.210 | 2.370–11.420 | <0.0001 | 1.826 | 0.742–4.491 | 0.1898 | 1.294 | 0.272–6.160 | 0.7464 |
| Anterior | 3.120 | 1.500–6.480 | 0.0020 | 2.727 | 1.162–6.400 | 0.0212 | 0.765 | 0.131–4.467 | 0.7663 |
| Posterolateral | 3.560 | 1.800–7.040 | <0.0001 | 2.691 | 1.300–5.570 | 0.0076 | 0.908 | 0.158–5.219 | 0.9143 |
aIn multivariate model 1, each variable was adjusted for initial PSA, pathologic Gleason score, and pathologic T stage; bIn multivariate model 2, all variables related to PSM were entered into the PSM cohort. CI: confidence interval; HR: hazard ratio; PSM: positive surgical margin; NSM: negative surgical margin; PSA: prostate-specific antigen
Sensitivity, specificity, and predictive values of intraoperative frozen sections showing positive surgical margins at each site
| All PSMs | ||||
| Periurethra tissue | 64.5 | 89.0 | 63.5 | 89.4 |
| Bladder neck | 19.0 | 98.4 | 50.0 | 93.5 |
| Dorsal vein site | 24.3 | 96.6 | 52.9 | 89.0 |
| PSM with Gleason pattern ≥4 | ||||
| Periurethra tissue | 83.3 | 84.2 | 39.7 | 97.6 |
| Bladder neck | 9.1 | 97.3 | 12.5 | 96.2 |
| Dorsal vein site | 31.3 | 95.3 | 29.4 | 95.7 |
PPV: positive predictive value; NPV: negative predictive value; PSMs: positive surgical margins
Multivariate logistic regression of factors predicting positive surgical margins including Gleason pattern ≥4 at each location
| Membranous urethra length on MRI (continuous) | 0.79 | 0.63–0.99 | 0.0376 | NA | 0.84 | 0.65–1.05 | 0.1516 | ||
| Maximal tumor percent of positive core (continuous) | 1.02 | 1.00–1.04 | 0.0834 | 1.05 | 1.02–1.10 | 0.0023 | |||
| Extracapsular extension of each site on MRI (yes | 4.58 | 1.24–17.32 | 0.0226 | 6.26 | 1.42–25.33 | 0.0106 | |||
| Positive frozen section of periurethra tissue (yes | 17.85 | 5.40–73.25 | <0.0001 | NA | NA | ||||
| Positive frozen section of bladder neck (yes | NA | NA | |||||||
| Positive frozen section of dorsal vein site (yes | NA | NA | |||||||
PSA: prostate-specific antigen; MRI: magnetic resonance imaging; NA: not analyzed; CI: confidence interval; OR: odds ratio